Oxford BioMedica PLC (OXB.L) Announces Update From Association for Research in Vision & Ophthalmology 2013
5/9/2013 6:50:07 AM
More...
|
Oxford BioMedica PLC (OXB.L) Abandons Prostate Cancer Vaccine Study
10/10/2012 7:53:35 AM
More...
|
Oxford BioMedica PLC (OXB.L) to Present at Conference
8/29/2012 9:49:54 AM
More...
|
Oxford BioMedica PLC (OXB.L) Announces Positive DSMB Review of Ongoing RetinoStat® and StarGen™ Clinical Studies
8/8/2012 12:24:03 PM
More...
|
Oxford BioMedica PLC (OXB.L) Receives Funding Award From the Foundation Fighting Blindness for ongoing UshStat® Phase I/IIa study
7/23/2012 10:37:16 AM
More...
|
Oxford BioMedica PLC (OXB.L) Announces Initiation of Phase II Collaborative Study for TroVax® in Colorectal Cancer
7/11/2012 9:57:55 AM
More...
|
Oxford BioMedica PLC (OXB.L) Announces Research and Development Collaboration for Glaucoma
10/31/2011 10:06:02 AM
More...
|
Oxford BioMedica PLC (OXB.L) Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B
10/18/2011 6:14:34 AM
More...
|
Oxford BioMedica PLC (OXB.L) Interim Results for the Six Months Ended 30 June 2011
8/31/2011 10:33:07 AM
More...
|
Oxford BioMedica PLC (OXB.L) Announces Interim Data from Highest (5x) Dose Cohort in ProSavin(R) Phase I/II Study in Parkinson's Disease
8/4/2011 7:58:24 AM
More...
|
|